Synergistic Activities of Colistin Combinations with Meropenem, Sulbactam, Minocycline, Disodium Fosfomycin, or Vancomycin Against Different Clones of Carbapenem-Resistant Acinetobacter baumannii Strains
Colistin became the primary treatment option for Acinetobacters that had developed a high rate of resistance to carbapenems which were the first-line therapy in the past, and now Acinetobacters become resistant to nearly all antibiotics. Because of the resistance potential to colistin and the concer...
Saved in:
Published in | Microbial drug resistance (Larchmont, N.Y.) Vol. 26; no. 5; p. 429 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.05.2020
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Colistin became the primary treatment option for Acinetobacters that had developed a high rate of resistance to carbapenems which were the first-line therapy in the past, and now Acinetobacters become resistant to nearly all antibiotics. Because of the resistance potential to colistin and the concerns about toxicity, especially for high doses, colistin combination therapies are preferred nowadays. In this study, we aimed to investigate whether combinations of colistin with meropenem, sulbactam, fosfomycin, vancomycin, and minocycline are synergic or not and to determine minocycline susceptibility rate, which is not in use in our country.
For the studied 23 Acinetobacter strains, the highest synergy was between colistin and vancomycin, which was shown in 4 (17.4%) strains. The synergy of colistin with meropenem and fosfomycin was detected for 1 (4.3%) strain, the synergy of colistin with minocycline was detected for 2 (8.6%) strains, and no synergy was detected for colistin-sulbactam combination. All the strains were susceptible to minocycline.
None of the antibiotic combinations was antagonistic. They had synergistic and additive interactions. Thus, these combinations can be used in clinical practices. The remarkable synergistic interaction of colistin-vancomycin combination and high susceptibility to minocycline highlight the need for more researches on these subjects. |
---|---|
AbstractList | Colistin became the primary treatment option for Acinetobacters that had developed a high rate of resistance to carbapenems which were the first-line therapy in the past, and now Acinetobacters become resistant to nearly all antibiotics. Because of the resistance potential to colistin and the concerns about toxicity, especially for high doses, colistin combination therapies are preferred nowadays. In this study, we aimed to investigate whether combinations of colistin with meropenem, sulbactam, fosfomycin, vancomycin, and minocycline are synergic or not and to determine minocycline susceptibility rate, which is not in use in our country.
For the studied 23 Acinetobacter strains, the highest synergy was between colistin and vancomycin, which was shown in 4 (17.4%) strains. The synergy of colistin with meropenem and fosfomycin was detected for 1 (4.3%) strain, the synergy of colistin with minocycline was detected for 2 (8.6%) strains, and no synergy was detected for colistin-sulbactam combination. All the strains were susceptible to minocycline.
None of the antibiotic combinations was antagonistic. They had synergistic and additive interactions. Thus, these combinations can be used in clinical practices. The remarkable synergistic interaction of colistin-vancomycin combination and high susceptibility to minocycline highlight the need for more researches on these subjects. |
Author | Sertcelik, Ahmet Bodur, Hurrem Mumcuoglu, Ipek Akinci, Esragul Baran, Irmak |
Author_xml | – sequence: 1 givenname: Ahmet surname: Sertcelik fullname: Sertcelik, Ahmet organization: Department of Infectious Diseases and Clinical Microbiology and Ankara Numune Training and Research Hospital, Ankara, Turkey – sequence: 2 givenname: Irmak surname: Baran fullname: Baran, Irmak organization: Department of Medical Microbiology, Ankara Numune Training and Research Hospital, Ankara, Turkey – sequence: 3 givenname: Esragul surname: Akinci fullname: Akinci, Esragul organization: Department of Infectious Diseases and Clinical Microbiology and Ankara Numune Training and Research Hospital, Ankara, Turkey – sequence: 4 givenname: Ipek surname: Mumcuoglu fullname: Mumcuoglu, Ipek organization: Department of Medical Microbiology, Ankara Numune Training and Research Hospital, Ankara, Turkey – sequence: 5 givenname: Hurrem surname: Bodur fullname: Bodur, Hurrem organization: Department of Infectious Diseases and Clinical Microbiology and Ankara Numune Training and Research Hospital, Ankara, Turkey |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31657659$$D View this record in MEDLINE/PubMed |
BookMark | eNo1UMtOwzAQtBCIlseRK_IHNMWusZMcq0IBqRUSBa7Iz7IosSvbAfUb-SlSCqedfc3szgk69MFbhC4oGVNS1VetieMJofWYkKo6QENaM1pU19fVAJ2k9EEI4VSwYzRgVPBS8HqIvldbb-MaUgaNpzrDJ2SwCQeHZ6HZlX0PWgVeZgg-4S_I73hpY9hYb9sRXnWNkjrLHi7BB73VDXg7wjeQgoGuxfOQXGi3GvwIh4hfpdf7FE_XEnzK_ahzNlqf8azpH9qLy6jkr0TxZFN_h-zb037L5rDTsxEr2bXSewC8ynHHdIaOnGySPf-Lp-hlfvs8uy8Wj3cPs-mi0EzwXNQ158pYoUVZaycUd9qRUvJSVk4xIYSuKDXEsd45xww3tNTGsNJWZMKMMpNTdLnn3XSqteZtE6GVcfv27-rkBwocf-E |
CitedBy_id | crossref_primary_10_1128_spectrum_01199_23 crossref_primary_10_3390_pharmaceutics12060501 crossref_primary_10_1080_14740338_2024_2416256 crossref_primary_10_3390_antibiotics10060646 crossref_primary_10_1007_s42770_023_01153_5 crossref_primary_10_3390_antibiotics9030119 crossref_primary_10_1016_j_ijmmb_2022_06_009 crossref_primary_10_1016_j_ijmmb_2021_04_006 crossref_primary_10_1021_acsinfecdis_0c00001 crossref_primary_10_3390_pharmaceutics13020162 crossref_primary_10_1016_j_jiph_2021_09_015 crossref_primary_10_1080_14786419_2020_1808635 crossref_primary_10_1038_s42003_020_01511_1 crossref_primary_10_1016_j_ijantimicag_2020_106271 crossref_primary_10_1128_spectrum_01928_22 crossref_primary_10_1007_s12088_022_01045_6 crossref_primary_10_1016_j_ijantimicag_2023_106880 crossref_primary_10_1248_bpb_b23_00642 crossref_primary_10_3390_antibiotics9080500 crossref_primary_10_1016_j_micpath_2023_106233 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1089/mdr.2019.0088 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1931-8448 |
ExternalDocumentID | 31657659 |
Genre | Journal Article |
GroupedDBID | --- .GJ 0R~ 123 29M 34G 39C 4.4 53G 7X7 88E 88I 8C1 8FE 8FH 8FI 8FJ AAHBH ABBKN ABUWG ACGFS ACGOD ACIWK ACPRK ADBBV AENEX AEUYN AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BBNVY BENPR BHPHI BNQNF BPHCQ BVXVI CAG CCPQU CGR COF CS3 CUY CVF DU5 DWQXO EBS ECM EIF EJD F5P FYUFA GNUQQ HCIFZ HMCUK IAO IER IHR IM4 INH INR ITC LK8 M1P M2P M7P MV1 NPM NQHIM O9- P2P PHGZT PQQKQ PROAC PSQYO RIG RML RMSOB UE5 UKHRP |
ID | FETCH-LOGICAL-c365t-9955bde6c679cf6b5fcf07a57a8fb3666c811d0f3844f3d5d17cdd37e8023dbd2 |
IngestDate | Thu Apr 03 06:58:32 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | checkerboard synergy minocycline colistin |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c365t-9955bde6c679cf6b5fcf07a57a8fb3666c811d0f3844f3d5d17cdd37e8023dbd2 |
PMID | 31657659 |
ParticipantIDs | pubmed_primary_31657659 |
PublicationCentury | 2000 |
PublicationDate | 2020-May |
PublicationDateYYYYMMDD | 2020-05-01 |
PublicationDate_xml | – month: 05 year: 2020 text: 2020-May |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Microbial drug resistance (Larchmont, N.Y.) |
PublicationTitleAlternate | Microb Drug Resist |
PublicationYear | 2020 |
SSID | ssj0005163 |
Score | 2.361498 |
Snippet | Colistin became the primary treatment option for Acinetobacters that had developed a high rate of resistance to carbapenems which were the first-line therapy... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 429 |
SubjectTerms | Acinetobacter baumannii - drug effects Anti-Bacterial Agents - pharmacology Bacteriological Techniques Carbapenems - pharmacology Colistin - pharmacology Drug Combinations Drug Resistance, Bacterial - drug effects Drug Synergism Fosfomycin - pharmacology Humans Meropenem - pharmacology Minocycline - pharmacology Sulbactam - pharmacology Vancomycin - pharmacology |
Title | Synergistic Activities of Colistin Combinations with Meropenem, Sulbactam, Minocycline, Disodium Fosfomycin, or Vancomycin Against Different Clones of Carbapenem-Resistant Acinetobacter baumannii Strains |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31657659 |
Volume | 26 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3JbtswEIaJpEWDXLq4-wYeilwkpZK1H1WjQVrURdA6RW4BRVKuUMsyZPngvmJfqjOkNqcpulwEQ7QkwvOZmiFnfhLyCoI1FoTMtgTEP5bnMWml3IcoBdgAb9bOvAynBqYfg9Nz7_2Ff7G3f2eQtbSp02P-_dq6kv-xKpwDu2KV7D9YtrspnIDPYF84goXh-Fc2_rzFyj0ltWwkXO0DkWsR2Um5wNNY0VdA7Nvku6lJ16nE-felLHRSziJlvNZUTPNlybdca49OlDCnyDeFcVKCa1tsuZYbKCvjC6CiTxjJnOXgYcKX9UYrtTFZoPy_rvuqUqYeZX2Sa3RUoTnBlXwcRVAl2kgZLiIs8xyXx_FOQ2d5miuVKFxGqjZzo2ruwZVb_AH_ofBL1zv1YlmbvFxzucjVSJ98Lfoi7zes0jO-7-CF1BUpJd9wxUG9FtYVmw9zJQu-KeeLjbpk1QgbN5MkY7tPSTyWemCPXceKPK3q2Y78ula_IdwfDOOe7vEvrxc7QnXWQqCQrINCp3pLwgFqq0Kx5joBBHJ-_OfWK2rfbdM-2Ye4BzdyxdmnNmUJnOdGJxZ68nqnH4fkoL32SoSkPKXZXXK7CXFoonm9R_bkckRu6U1PtyNyMG3SOUbk6EwLp29NOuvrANcmPaJnvaT69j75MSCd9qTTMqMt6XRIOkXSaUe6STvOTTqg3KQt47Rn3KRlRXvCaUM47QinmnD18GsIpzuE045w2hD-gJyfvJ1NTq1mGxKLu4FfW3Hs-6mQAQ_CmGdB6mc8s0PmhyzKUhfCfx45jrAzF_DKXOELJ-RCuKFEbUWRivFDcmMJ_XpMqOtz2-bjNApC6UWSRTHzWCSiUDDMF02fkEfacpcrrTVz2dr06W9bnpHDnvjn5GYGg5t8AZ5ynb5U-PwEAQnI9A |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synergistic+Activities+of+Colistin+Combinations+with+Meropenem%2C+Sulbactam%2C+Minocycline%2C+Disodium+Fosfomycin%2C+or+Vancomycin+Against+Different+Clones+of+Carbapenem-Resistant+Acinetobacter+baumannii+Strains&rft.jtitle=Microbial+drug+resistance+%28Larchmont%2C+N.Y.%29&rft.au=Sertcelik%2C+Ahmet&rft.au=Baran%2C+Irmak&rft.au=Akinci%2C+Esragul&rft.au=Mumcuoglu%2C+Ipek&rft.date=2020-05-01&rft.eissn=1931-8448&rft.volume=26&rft.issue=5&rft.spage=429&rft_id=info:doi/10.1089%2Fmdr.2019.0088&rft_id=info%3Apmid%2F31657659&rft_id=info%3Apmid%2F31657659&rft.externalDocID=31657659 |